MedTrace Logo

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

NCT04575194 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-10-08

No results posted yet for this study

Summary

The aim of the present study is to compare the efficacy of liraglutide vs. naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after a test meal. The study will include 40 patients, who will further be divided into two treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). The patients will be examined at baseline, 3 and 6 months after the treatment initiation.

Conditions

Interventions

DRUG

Liraglutide 6 MG/ML [Saxenda]

3 mg of sc liraglutide daily plus lifestyle intervention

DRUG

Naltrexone-Bupropion Combination

32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention

Sponsors & Collaborators

  • Athens Medical Center

    collaborator OTHER

  • National and Kapodistrian University of Athens

    lead OTHER

Principal Investigators

  • Alexandros Kokkinos, MD, PhD · National and Kapodistrian University of Athens

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-08
Primary Completion
2022-09-30
Completion
2023-05-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575194 on ClinicalTrials.gov